Knight Therapeutics (TSX:GUD) Days Sales Outstanding : 87.15 (As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Knight Therapeutics Days Sales Outstanding?

Knight Therapeutics's average Accounts Receivable for the three months ended in Sep. 2024 was C$88.1 Mil. Knight Therapeutics's Revenue for the three months ended in Sep. 2024 was C$92.3 Mil. Hence, Knight Therapeutics's Days Sales Outstanding for the three months ended in Sep. 2024 was 87.15.

The historical rank and industry rank for Knight Therapeutics's Days Sales Outstanding or its related term are showing as below:

TSX:GUD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 73.18 Med: 96.62 Max: 341.23
Current: 90.69

During the past 11 years, Knight Therapeutics's highest Days Sales Outstanding was 341.23. The lowest was 73.18. And the median was 96.62.

TSX:GUD's Days Sales Outstanding is ranked worse than
68.18% of 971 companies
in the Drug Manufacturers industry
Industry Median: 71.75 vs TSX:GUD: 90.69

Knight Therapeutics's Days Sales Outstanding declined from Sep. 2023 (104.06) to Sep. 2024 (87.15).

Knight Therapeutics Days Sales Outstanding Historical Data

The historical data trend for Knight Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Knight Therapeutics Days Sales Outstanding Chart

Knight Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

341.23

135.70

88.37

93.42

102.10

Knight Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Days Sales Outstanding	Get a 7-Day Free Trial															104.06	105.12	92.03	81.60	87.15

Competitive Comparison of Knight Therapeutics's Days Sales Outstanding

For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Knight Therapeutics's Days Sales Outstanding Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Knight Therapeutics's Days Sales Outstanding falls into.

Knight Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Knight Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (94.89	+	88.722)	/	2 )	/	328.199	*	365
=	91.806					/	328.199	*	365
=	102.10

Knight Therapeutics's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

	Days Sales Outstanding (Q: Sep. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2024 )	+	Accounts Receivable (A: Sep. 2024 ))	/	count )	/	Revenue (A: Sep. 2024 )	*	Days in Period
=	( (84.976	+	91.25)	/	2 )	/	92.263	*	365 / 4
=	88.113					/	92.263	*	365 / 4
=	87.15

Knight Therapeutics (TSX:GUD) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Knight Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Knight Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Knight Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (TSX:GUD) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

KHTRF:USA

Address

3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8

Website

https://www.gud-knight.com

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets . The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically the company generates revenue from Brazil, Colombia, Argentina, Rest of LATAM, Canada, and Other, with the majority revenue generated from the Brazil region.

Executives

Sime Armoyan	10% Security Holder
Samira Sakhia	Director, Senior Officer
Amal Khouri	Senior Officer
Jonathan Ross Goodman	Director, Director or Senior Officer of 10% Security Holder
Robert Nathaniel Lande	Director
Janice Jean Murray	Director
Nicolas Sujoy	Director
Long Zone Holdings Inc.	10% Security Holder
Arvind Utchanah	Senior Officer
Michael Joseph Tremblay	Director
James Gale	Director
Michael Dehn	Director, Senior Officer
Andrew Moor	Senior Officer
Patrick Mcclymont	Senior Officer
Kevin Drew Nabholz	Director

Knight Therapeutics Headlines

No Headlines